



US009220698B2

(12) **United States Patent**  
**Ault et al.**

(10) **Patent No.:** **US 9,220,698 B2**  
(45) **Date of Patent:** **\*Dec. 29, 2015**

(54) **METHOD FOR DELIVERING A PHARMACEUTICAL COMPOSITION TO PATIENT IN NEED THEREOF**

(75) Inventors: **Brian Ault**, Wilmington, DE (US);  
**Mark Sostek**, Wilmington, DE (US);  
**Everardus Orlemans**, Chapel Hill, NC (US);  
**John R. Plachetka**, Chapel Hill, NC (US)

(73) Assignees: **Pozen Inc.**, Chapel Hill, NC (US);  
**Horizon Pharma USA, Inc.**, Deerfield, IL (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 553 days.  
  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/553,107**

(22) Filed: **Sep. 3, 2009**

(65) **Prior Publication Data**

US 2010/0062064 A1 Mar. 11, 2010

**Related U.S. Application Data**

(60) Provisional application No. 61/095,584, filed on Sep. 9, 2008.

(51) **Int. Cl.**  
**A61K 31/4439** (2006.01)  
**A61K 31/192** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 31/192** (2013.01); **A61K 31/4439** (2013.01)

(58) **Field of Classification Search**  
CPC ..... **A61K 31/4439**; **A61K 31/192**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

- 4,198,390 A 4/1980 Rider
- 4,255,431 A 3/1981 Junggren et al.
- 4,344,929 A 8/1982 Bonsen et al.
- 4,508,905 A 4/1985 Junggren et al.
- 4,554,276 A 11/1985 LaMattina
- 4,562,261 A 12/1985 Hirata et al.
- 4,619,934 A 10/1986 Sunshine et al.
- 4,676,984 A 6/1987 Wu et al.
- 4,704,278 A 11/1987 Wu et al.
- 4,726,951 A 2/1988 Panoz et al.
- 4,738,974 A 4/1988 Brandstrom
- 4,757,060 A 7/1988 Lukacsko et al.
- 4,758,579 A 7/1988 Kohl et al.
- 4,766,117 A 8/1988 Crawford et al.
- 4,786,505 A 11/1988 Lovgren et al.
- 4,853,230 A 8/1989 Lovgren et al.
- 4,865,847 A 9/1989 Gosswein
- 4,948,581 A 8/1990 Sawayanagi et al.
- 4,965,065 A 10/1990 Lukacsko et al.
- 5,026,560 A 6/1991 Makino et al.
- 5,035,899 A 7/1991 Saeki et al.

- 5,037,815 A 8/1991 Lukacsko et al.
- 5,043,358 A 8/1991 Lukacsko et al.
- 5,051,262 A 9/1991 Panoz et al.
- 5,093,132 A 3/1992 Makino et al.
- 5,204,118 A 4/1993 Goldman et al.
- 5,260,333 A 11/1993 Lukacsko et al.
- 5,364,616 A 11/1994 Singer et al.
- 5,373,022 A 12/1994 Fawzi et al.
- 5,409,709 A 4/1995 Ozawa et al.
- 5,417,980 A 5/1995 Goldman et al.
- 5,466,436 A 11/1995 Stables
- 5,514,663 A 5/1996 Mandel
- 5,601,843 A 2/1997 Gimet et al.
- 5,631,022 A 5/1997 Mandel et al.
- 5,643,960 A 7/1997 Breitner et al.
- 5,667,802 A 9/1997 Grimberg
- 5,679,376 A 10/1997 Stevens et al.
- 5,686,105 A 11/1997 Kelm et al.
- 5,702,723 A 12/1997 Griffin
- 5,714,504 A 2/1998 Lindberg et al.
- 5,716,648 A 2/1998 Halskov et al.
- 5,750,531 A 5/1998 Lee et al.
- 5,817,338 A 10/1998 Bergstrand et al.
- 5,817,340 A 10/1998 Roche et al.
- 5,840,737 A 11/1998 Phillips
- 5,900,424 A 5/1999 Kallstrom et al.
- 5,955,451 A 9/1999 Lichtenberger et al.
- 6,013,281 A 1/2000 Lundberg et al.
- 6,025,395 A 2/2000 Breitner et al.
- 6,093,734 A 7/2000 Garst et al.
- 6,132,768 A 10/2000 Sachs et al.
- 6,132,771 A 10/2000 Depui et al.
- 6,136,344 A 10/2000 Depui et al.
- 6,160,020 A 12/2000 Ohannesian et al.
- 6,162,816 A 12/2000 Bohlin et al.
- 6,183,776 B1 2/2001 Depui et al.
- 6,183,779 B1 2/2001 Ouali et al.
- 6,207,188 B1 3/2001 Gustavsson et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

AU 2006235929 11/2006  
CA 2139653 7/2000

(Continued)

**OTHER PUBLICATIONS**

Abelo et al., "Pharmacodynamic modeling of reversible gastric acid pump inhibition in dog and man," *European Journal of Pharmaceutical Sciences*, 14, pp. 339-346 (2001).

(Continued)

*Primary Examiner* — Gina Justice

(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.

**7 Claims, 9 Drawing Sheets**

(56)

References Cited

U.S. PATENT DOCUMENTS

6,231,888	B1	5/2001	Lerner et al.	
6,287,600	B1	9/2001	Ouali et al.	
6,365,184	B1 *	4/2002	Depui et al. ....	424/472
6,369,085	B1	4/2002	Cotton et al.	
6,372,255	B1	4/2002	Saslowski et al.	
6,387,410	B1	5/2002	Woolfe et al.	
6,395,298	B1	5/2002	Flanagan et al.	
6,428,810	B1	8/2002	Bergstrand et al.	
6,485,747	B1	11/2002	Flanagan et al.	
6,489,346	B1	12/2002	Phillips	
6,544,556	B1	4/2003	Chen et al.	
6,599,529	B1	7/2003	Skinhoj et al.	
6,610,323	B1	8/2003	Lundberg et al.	
6,613,354	B2	9/2003	Depui et al.	
6,632,451	B2	10/2003	Penhasi et al.	
6,641,838	B2	11/2003	Pather et al.	
6,645,988	B2	11/2003	Phillips	
6,673,819	B2	1/2004	Bergman et al.	
6,685,964	B1	2/2004	Bartholomaeus et al.	
6,699,885	B2	3/2004	Phillips	
6,713,089	B1	3/2004	Bertelsen et al.	
6,749,867	B2	6/2004	Robinson et al.	
6,780,882	B2	8/2004	Phillips	
6,787,164	B2	9/2004	Gelber et al.	
6,797,283	B1	9/2004	Edgren et al.	
6,869,615	B2	3/2005	Chen et al.	
6,875,872	B1	4/2005	Lindberg et al.	
6,926,907	B2 *	8/2005	Plachetka .....	424/472
7,029,701	B2	4/2006	Chen	
7,094,425	B2	8/2006	Scott et al.	
7,399,772	B2	7/2008	Phillips	
7,411,070	B2	8/2008	Cotton et al.	
7,488,497	B2	2/2009	Depui et al.	
7,745,466	B2	6/2010	Cotton et al.	
7,785,626	B2	8/2010	Pettersson et al.	
7,846,914	B2	12/2010	Petrus	
8,206,741	B2	6/2012	Plachetka	
2001/0025107	A1	9/2001	Barberich et al.	
2002/0012676	A1	1/2002	Lundberg et al.	
2002/0042433	A1	4/2002	Yelle et al.	
2002/0044962	A1	4/2002	Cherukuri et al.	
2002/0045184	A1	4/2002	Chen	
2002/0086029	A1	7/2002	Lundberg et al.	
2002/0090395	A1	7/2002	Woolfe et al.	
2003/0008903	A1	1/2003	Barberich et al.	
2003/0113375	A1	6/2003	Lundberg et al.	
2003/0215527	A1	11/2003	Phillips	
2003/0232080	A1	12/2003	Pather et al.	
2004/0048896	A1	3/2004	Phillips	
2004/0121004	A1	6/2004	Taneja	
2004/0131676	A1	7/2004	Taneja	
2004/0171646	A1	9/2004	Phillips	
2005/0004171	A1	1/2005	Phillips	
2005/0042304	A1	2/2005	Phillips	
2005/0054682	A1	3/2005	Phillips	
2005/0147668	A1	7/2005	Bertelsen et al.	
2005/0163847	A1	7/2005	Cheng et al.	
2005/0227949	A1	10/2005	Edalatpour	
2005/0249806	A1	11/2005	Proehl et al.	
2006/0165797	A1	7/2006	Plachetka	
2006/0177504	A1	8/2006	Sundharadas	
2006/0178348	A1	8/2006	Plachetka	
2006/0178349	A1	8/2006	Plachetka	
2006/0287284	A1	12/2006	Schutze et al.	
2007/0122470	A1	5/2007	Johansson et al.	
2007/0154542	A1	7/2007	Tananbaum et al.	
2007/0184078	A1	8/2007	Chen	
2007/0237820	A1	10/2007	Cheng et al.	
2007/0243251	A1	10/2007	Taneja	
2008/0031941	A1	2/2008	Pettersson	
2008/0031950	A1	2/2008	Sesha	
2008/0103169	A1	5/2008	Phillips	
2009/0074863	A1	3/2009	Taneja	
2009/0075950	A1	3/2009	Taneja	
2010/0172983	A1	7/2010	Plachetka	

2010/0178334	A1	7/2010	Johansson et al.
2010/0330179	A1	12/2010	Ault et al.
2012/0064156	A1	3/2012	Plachetka

FOREIGN PATENT DOCUMENTS

DE	4035455	5/1992
DE	19801811	12/2004
EP	0005129	4/1981
EP	0124495	1/1987
EP	0174726	4/1989
EP	0320550	6/1989
EP	0320551	6/1989
EP	0166287	8/1989
EP	0167958	1/1991
EP	0244380	1/1993
EP	0426479	2/1994
EP	0550083	3/1999
EP	1068867	9/2003
EP	1726300	11/2006
EP	1726301	11/2006
EP	1020461	7/2009
GB	2105193	3/1983
GB	2163747	3/1986
GB	2216413	10/1989
JP	2005-145894	6/2005
WO	8503443	8/1985
WO	9006925	6/1990
WO	9116886	11/1991
WO	9116895	11/1991
WO	9116896	11/1991
WO	9119711	12/1991
WO	9119712	12/1991
WO	9311750	6/1993
WO	9312817	7/1993
WO	9407541	4/1994
WO	9427988	12/1994
WO	9501977	1/1995
WO	9532959	12/1995
WO	9605177	2/1996
WO	9605199	2/1996
WO	9614839	5/1996
WO	9622780	8/1996
WO	9711701	4/1997
WO	9725064	7/1997
WO	9813073	4/1998
WO	9822117	5/1998
WO	9822118	5/1998
WO	9854171	12/1998
WO	9900380	1/1999
WO	9912524	3/1999
WO	9929320	6/1999
WO	9966919	12/1999
WO	0001368	1/2000
WO	0015195	3/2000
WO	0056339	9/2000
WO	0071122	11/2000
WO	0072838	12/2000
WO	0078293	12/2000
WO	0124777	4/2001
WO	0166088	9/2001
WO	0222108	3/2002
WO	02066002	8/2002
WO	03017980	3/2003
WO	2004062552	7/2004
WO	2004064815	8/2004
WO	2005074536	8/2005
WO	2005074930	8/2005
WO	2006044202	4/2006
WO	2007064274	6/2007
WO	2007078874	7/2007
WO	2008101060	8/2008

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	2009012393	1/2009
WO	2009145905	12/2009
WO	2010151697	12/2010

## OTHER PUBLICATIONS

Alexander, et al., "Pilot Evaluation of a Novel Combination Tablet (PN 400) Containing a Proton Pump Inhibitor and a Nonsteroidal Anti-Inflammatory Drug in Prevention of Upper Gastrointestinal Mucosal Injury," *American Journal of Gastroenterology*, 100(9), p. S68, 135 (2005).

Andersson, "Pharmacokinetics, metabolism and interactions of acid pump inhibitors," *Clin. Pharmacokinet.* 31(1)9-28 (Jul. 1996).

Anonymous: "A 12-month, phase 3, open-label, multi-center study to evaluate the long-term safety of PN 400" Internet article (Sep. 11, 2007), XP00255347, retrieved from the internet, URL:<http://clinicaltrials.gov/show/NCT00527904>.

Anonymous: "PK Study to evaluate Esomeprazole plasma levels following the administration of PN 400" Internet article (Feb. 11, 2008), XP002553435, retrieved from the internet: URL:<http://clinicaltrials.gov/show/NCT00599404>.

Anonymous: "Study evaluating the bioavailability of Naproxen 500 mg in three formulations," Internet article (May 11, 2008), XP002553436m retrieved from the internet: URL:<http://clinicaltrials.gov/show/NCT00665743>.

Arthrotec Data sheet (Aug. 2009).

Awtry, et al., "Aspirin," *Circulation* 101:1206-1218 (2000).

Ballinger, et al., "COX-2 Inhibitors vs. NSAIDs in Gastrointestinal Damage and Prevention," *Exp. Opin. Pharmacother.* 2(1):31-40 (2001).

Barnett et al., "Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa," *Br. J. Pharmac.*, 83, pp. 75-82 (1984).

Berardi et al., "Elevation of Gastric pH with Ranitidine does not affect the release characteristics of sustained release Ibuprofen tablets," *Biopharmaceutics & Drug Disposition*, 9: pp. 337-347 (1988).

Bergmann et al., "Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses," *Clin. Pharmacol. Ther.*, 52, pp. 413-416 (Oct. 1992).

Bianchi Porro et al., "Pantoprazole vs placebo in prevention of NSAID-induced ulcers," *Gastroenterology*, 114(4), p. A74 (1998).

Bianchi Porro, et al., "Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study," *Ital. J. Gastroenterol. Hepatol.*, 30, pp. 43-47 (1998).

Bianchi Porro, et al., "Why Are Non-Steroidal Anti-Inflammatory Drugs Important in Peptic Ulcers?" *Aliment. Pharmacol. Therap*, 1, pp. 540S-547S (1987).

Bigard English translation—Bigard, et al. "Effet protecteur de l'omeprazole sur les lesions gastriques induites par une prise unique d'aspirine chez l'homme," *Gastroenterol. Clin. Biol.*, 12, pp. 770-771 (1998).

Bigard et al., "Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects," *Gut*, 29(5), p. A712, T49 (1988).

Bigard et al., "Effet protecteur de l'omeprazole sur les lesions gastriques induites par une prise unique d'aspirine chez l'homme," *Gastroenterol. Clin. Biol.*, 12, pp. 770-771 (1998).

Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," *N. Engl. J. Med.*, 343, pp. 1520-1528 (2000).

Brown et al., "Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs," *Pract. Drug Safety*, 21, pp. 503-512 (1999).

Brown, et al., "Asprin- and Indomethacin-Induced Ulcers and Their Antagonism by Antihistamines," *Euro. J. Pharm.*, 51, pp. 275-283 (1978).

Byrn et al., "Pharmaceutical solids: A strategic approach to regulatory considerations," *Pharm. Res.*, 12(7), pp. 945-954 (1995).

Carrasco-Portugal, et al., "Bioavailability of a Formulation Containing a Diclofenac-Ranitidine Combination," *Proc. West. Pharmacol. Soc.*, 45, pp. 8-10 (2002).

Chan et al., "Eradication of H. pylori versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users: A prospective randomized study," *Gastroenterology*, 114, p. A87, G0356 (1998).

Chan, et al., "Clopidogrel versus Aspirin and Esomeprazole to prevent recurrent ulcer bleeding," *New Eng. J. Med.* 352, pp. 238-244 (2005).

Chandrarnouli et al., *J. Pharmaceutical Pain and Symptom Control*, pp. 27-40 (2000).

Chang et al., "Polymethacrylates," *Handbook of Pharmaceutical Excipients*, Fifth Edition, Ed. Raymond C. Rowe, Paul J. Sheskey and Sian C. Owen, London: Pharmaceutical Press, pp. 553-560 (2006).

Cullen et al., "Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users," *Aliment. Pharmacol. Ther.*, 12, pp. 135-140 (1998).

Dajani, Esam Z., "Perspective on the Gastric Antisecretory Effects of Misoprostol in Man," *Prostaglandins*, 33, pp. 68-77 (1987).

Daneshmend et al., "Abolition by omeprazole of aspirin-induced gastric mucosal injury in man," *Gut*, 31, pp. 514-517 (1990).

Daneshmend et al., "Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by Famotidine," *Gastroenterology*, 97, pp. 944-949 (1989).

Dent et al., "Why proton pump inhibition should heal and protect against nonsteroidal anti-inflammatory drug ulcers," *Am. J. Med.*, 104, pp. 52S-55S (1998).

Ehsanullah et al., "Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine," *BMJ*, 297, pp. 1017-1021 (Oct. 1988).

Ekstrom et al., "Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy," *Scand. J. Gastroenterol.*, 31, pp. 753-758 (1996).

Ene et al., "A study of the inhibitory effects of SCH 28080 on gastric secretion in man," *Br. J. Pharmac.*, 76, pp. 389-391 (1982).

Erlandsson et al., "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a triphenylcarbamoylcellulose-based stationary phase," *J. Chromatog.*, 532, pp. 305-319 (1990).

Feldman et al., "Effect on antacid on absorption on enteric-coated aspirin," *JAMA*, 227(6), pp. 660-661 (1974).

Florence et al., "Novel oral drug formulations their potential in modulating adverse effects," *Drug Safety*, 10(3), pp. 233-266 (1994).

Frank, et al., "Reduction of Indomethacin Induced Gastroduodenal Mucosal Injury and Gastro-intestinal Symptoms with Cimetedine in Normal Subjects," *J. Rheum.*, 16, pp. 1249-1252 (1989).

Gengo, et al., "Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events," *J. Clin. Pharmacol.*, 48, pp. 335-343 (2008).

Goldstein et al., "116 A single tablet multilayer formulation of enteric-coated naproxen coupled with non-enteric-coated omeprazole is associated with a significantly reduced incidence of gastric ulcers vs. enteric-coated naproxen: A prospective, randomized, double-blind study," *Gastroenterology*, Elsevier, Philadelphia, PA, 134(4), p. A-19 (Apr. 1, 2008).

Goldstein, et al., "PN400 Significantly Improves Upper Gastrointestinal Tolerability Compared with Enteric-Coated Naproxen Alone in Patients Requiring Chronic NSAID Therapy: Results from Two Prospective, Randomized, Controlled Trials," Pozen Inc. sponsored study, 74th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA (Oct. 27, 2009).

Goldstein, et al., "PN400 Significantly Reduces the Incidence of Gastric Ulcers Compared With Enteric-Coated Naproxen in Patients Requiring Chronic NSAID Therapy Regardless of Low-Dose Aspirin Use: Results from Two Prospective, Randomized Controlled Trials," Pozen Inc. sponsored study, ACR/ARHP Mtg, (Oct. 16-21, 2009).

Graham, et al., "Duodenal and Gastric Ulcer Prevention with Misoprostol in Arthritis Patients Taking NSAIDs," *Ann. Intern. Med.* 119(4):257-262 (Aug. 1993).

(56)

## References Cited

## OTHER PUBLICATIONS

- Grosser et al., "Thromboxane Generation," in Platelets, Alan Michelson ed., Elsevier Science, pp. 565-574 (2007).
- Gurbel et al., "Abstract 4267: PA32520 (Single-tablet of enteric coated aspirin 325 mg + immediate-release omeprazole 20 mg): Aspirin therapy combining greater thromboxane suppression and lower upper gastrointestinal damage," *Circulation*, 118, p. S855 (2008).
- Hart, et al., "Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease," *Pharmacotherapy* 23 (5):579-584 (2003).
- Hassan-Alin et al., "T1651 lack of drug-drug interaction between esomeprazole and naproxen in healthy subjects," *Gastroenterology*, 124(4), Supp. 1, p. A541 (Apr. 2003).
- Hawkey et al., "Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs," *N. Engl. J. Med.*, 338, pp. 727-734 (1998).
- Hawkey et al., "Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions," *Am. J. Med.*, 104, pp. 67S-74S (1998).
- Office Action dated Apr. 22, 2004 issued for U.S. Pat. No. 6,926,907.
- Office Action dated Oct. 10, 2004 issued for U.S. Pat. No. 6,926,907.
- Notice of Allowance dated Mar. 29, 2005 issued for U.S. Pat. No. 6,926,907.
- Office Action dated Mar. 30, 2009 issued for U.S. Pat. No. 8,206,741.
- Office Action dated Nov. 19, 2009 issued for U.S. Pat. No. 8,206,741.
- Office Action dated Oct. 25, 2010 issued for U.S. Pat. No. 8,206,741.
- Office Action dated Jun. 16, 2011 issued for U.S. Pat. No. 8,206,741.
- Interview Summary dated Nov. 15, 2011 issued for U.S. Pat. No. 8,206,741.
- Interview Summary dated Mar. 7, 2012 issued for U.S. Pat. No. 8,206,741.
- Interview Summary dated Apr. 19, 2012 issued for U.S. Pat. No. 8,206,741.
- Notice of Allowance dated May 13, 2012 issued for U.S. Pat. No. 8,206,741.
- IPER issued for WO 2010/029335, Mar. 2011.
- ISR issued for WO 2010/029335, Nov. 2009.
- Supplemental ISR issued for WO 2010/029335, Sep. 2010.
- Written Opinion issued for WO 2010/029335, Mar. 2011.
- U.S. Appl. No. 13/475,446, filed May 18, 2012.
- Preliminary Amendment for U.S. Appl. No. 13/475,446, filed May 18, 2012.
- Hawkey et al., "Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine," *Aliment. Pharmacol. Therap.*, 2, pp. 245-252 (1988).
- Hawkey et al., *Scandinavian J. Gastroenterology*, pp. 124-127 (1996).
- Handbook of Pharmaceutical Excipients, 5th Edition (2006).
- Hawkey et al., *Scandinavian J. Gastroenterology*, pp. 170-173 (1986).
- Hawkins & Hanks, *J. Pain and Symptom Management*, pp. 140-151 (2000).
- Helander et al., "Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine," *Scand. J. Gastroenterol.*, 25, pp. 799-809 (1990).
- Histamine H2 antagonist information on drugs.com website, downloaded Feb. 20, 2012.
- Hogan et al., "Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta," *Can. Med. Assoc.*, 151(3), pp. 315-322 (1994).
- Howden, "Clinical Pharmacology of Omeprazole," *Clin. Pharmacokinet.*, 20(1), pp. 38-49 (1991).
- Ife et al., "Reversible inhibitors of the Gastric (H<sub>2</sub>sup.+K<sub>2</sub>sup.+)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines," *J. Med. Chem.*, 35, pp. 3413-3422 (1992).
- Jiraneck, et al., "Misoprostol Reduces Gastrointestinal Injury From One Week of Aspirin: An Endoscopic Study," *Gastroenterology*, 96, pp. 656-661 (1989).
- Katz et al., "Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole," *Aliment. Pharmacol. Ther.*, 14, pp. 709-714 (2000).
- Keeling et al., "SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H<sub>2</sub>sup.+K<sub>2</sub>sup.+)-ATPase," *Biochemical Pharmacology*, 42(1), pp. 123-130 (1991).
- Kephart et al., "Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population," *Clin. Ther.*, 17, pp. 1159-1173 (1995).
- Kimmey et al., "Role of H<sub>2</sub>-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents," *Am. J. Med.*, 84, pp. 49-52 (1988).
- Kitchingman, et al., "Enhanced Gastric Mucosal Bleeding with Doses of Aspirin Used for Prophylaxis and Its Reduction by Ranitidine," *Br. J. Clin. Pharmacol.*, 28, pp. 581-585 (1989).
- Konturek et al., "Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs," *Gastroenterology*, 86(1), pp. 71-77 (1984).
- Lad et al., "Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression," *Can. J. Gastroenterol.*, 13, pp. 135-142 (1999).
- Lanas, A., "Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both," *Digestive and Liver Disease*, 36, pp. 655-657 (2004).
- Lanza, et al., "A Double-Blind Placebo-Controlled Comparison of the Efficacy and Safety of 50, 100, and 200 ug of Misoprostol QID in the Prevention of Ibuprofen-Induced Gastric and Duodenal Mucosal Lesions and Symptoms," *Am. J. Gastroenterol.*, 84(6), pp. 633-636 (1989).
- Lanza, et al., "Double-Blind, Placebo-Controlled Endoscopic Comparison of the Mucosal Protective Effects of Misoprostol Versus Cimetidine on Tolmetin-Induced Mucosal Injury to the Stomach and Duodenum," *Gastroenterology*, 95, pp. 289-294 (1988).
- Larsson et al., "Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo," *Scand J Gastroenterol Suppl.*, 108, pp. 23-35 (1985).
- Lee et al., "Omeprazole prevents indomethacin-induced gastric ulcers in rabbits," *Aliment. Pharmacol. Ther.*, 10, pp. 571-576 (1996).
- Leese, et al., "Effects of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial," *J. Clin. Pharmacol.*, 40, pp. 124-132 (2000).
- Leonards et al., "Reduction or prevention of aspirin-induced occult gastrointestinal blood loss in man," *Clinical Pharmacology and Therapeutics*, 10(4), pp. 571-575 (1969).
- Lichtenberger et al., "Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats," *Gastroenterology*, 111, pp. 990-995 (1996).
- Lin and Lu, "Role of pharmacokinetics and metabolism in drug discovery and development," *Pharmacological Reviews*, 49(4), pp. 403-449 (1997).
- Maggi et al., *Int. J. Pharm.*, pp. 173-179 (1993).
- Mason et al., "Kinetics of aspirin, salicylic acid, and salicyric acid following oral administration of aspirin as a tablet and two buffered solutions," *J. Pharmaceutical Sciences*, 70(3), pp. 262-265 (1981).
- Mattson et al., "Omeprazole provides protection against experimentally induced gastric mucosal lesions," *Eur. J. Pharmacol.*, 91, pp. 111-114 (1983).
- McKeage et al., "Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults," *Drugs*, 68(11), pp. 1571-1607 (2008).
- Miner et al., "Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed dose combination of PN400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric coated esomeprazole 20 mg: a randomized, open-label, phase 1 study in healthy volunteers," *Alimentary pharmacology and therapeutics*, 32, pp. 414-424, table 1 (2010).
- Miner et al., "T1969 gastric acid suppression with PN400, a single-tablet, multilayer, fixed-dose formulation combining an immediate-release esomeprazole layer and an enteric-coated naproxen core," *Gastroenterology*, Elsevier, Philadelphia, PA, 136(5), p. A-611 (May 1, 2009).

(56)

## References Cited

## OTHER PUBLICATIONS

- Miner et al., "T1972 Pharmacokinetics of Naproxen and Esomeprazole in PN400, a single-tablet, multilayer formulation of enteric-coated Naproxen coupled with immediate-release Esomeprazole," *Gastroenterology*, Elsevier, Philadelphia, PA, 136(5), p. A-612 (May 1, 2009).
- Morgner et al., "Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers," *Expert opinion on pharmacotherapeutics*, 8(7), pp. 975-988 (2007).
- Morris, et al., "Gastric Cytoprotection is Secondary to Increased Mucosal Fluid Secretion: A Study of Six Cytoprotective Agents in the Rat," *J. Clin. Gastroenterol.*, 27, Supp. 1, pp. S53-S63 (1998).
- Morrison et al., "The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials," *JADA*, 131, pp. 1729-1737 (2000).
- Muller English translation—Muller, et al., "Untersuchungen zur Schutzwirkung von Lansoprazol auf die menschliche Magenschleimhaut gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 47, pp. 758-760 (1997).
- Muller English translation—Muller, et al., "Verbesserung der gastroduodenalen Vertraglichkeit von Azetylsalizylsäure durch Ranitidin," *Arzneimittel-Forschung/Drug Res.*, 41(1), pp. 638-639 (1991).
- Muller, et al., "Untersuchungen zur Schutzwirkung von Lansoprazol auf die menschliche Magenschleimhaut gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 47, pp. 758-760 (1997).
- Muller, et al., "Verbesserung der gastroduodenalen Vertraglichkeit von Azetylsalizylsäure durch Ranitidin," *Arzneimittel-Forschung/Drug Res.*, 41(1), pp. 638-639 (1991).
- Naesdal, et al., Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-Inflammatory Drugs, *European Journal of Gastroenterology & Hepatology*, 13(12), pp. 1401-1406 (2001).
- Naprosyn EC Label, Roche (1999).
- Nefesoglu, et al., "Interaction of Omeprazole with Enteric-Coated Salicylate Tablets," *International Journal of Clinical Pharmacology and Therapeutics*, 36(10), pp. 549-553 (1998).
- Neuvonen et al., "Enhancement of drug absorption of antacids," *Clin. Pharmacokinet.*, 27(2), pp. 120-128 (1994).
- Oddsson et al., "Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects," *Scand. J. Gastroenterol.*, 25, pp. 231-234 (1990).
- Oddsson, et al., "Comparison between Ranitidine and Omeprazole for Protection against Gastroduodenal Damage Caused by Naproxen," *Scand. J. Gastroenterol.*, 27, pp. 1045-1048 (1992).
- Okabe et al., "Antisecretory effect of leminoprazole on histamine-stimulated gastric acid secretion in dogs: potent local effect," *Jpn. J. Pharmacol.*, 69, pp. 91-100 (1995).
- Okabe et al., "Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs," *Journal of Physiology and Pharmacology*, 52(4), pp. 639-656 (2001).
- Office Communication issued in Egyptian Patent Application No. 2121/2011, dated Apr. 13, 2013. (English summary of Arabic text).
- Panara et al., "Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases," *British Journal of Pharmacology*, 116, pp. 2429-2434 (1995).
- Pang et al., "Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette review series)" *Drug Metabolism and Disposition*, 31(12), pp. 1507-1519 (2003).
- Patrono, et al., "Low-Dose Aspirin for the Prevention of Atherothrombosis," *New Eng. J. Med.*, 353, pp. 2373-2383 (2005).
- Petersen, "Doubts are raised on the safety of 2 popular arthritis drugs," *NY Times*, p. C1 (May 22, 2001).
- Pilbrant et al., "Development of an Oral Formulation of Omeprazole," *Scand. J. Gastroenterol.*, 20, Supp. 108, pp. 113-120 (1985).
- Pirmohamed et al., "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients," *Br. Med. J.*, 329, pp. 15-19 (2004).
- Porter S.C., "Coating of Pharmaceutical Dosage Forms," in: A. Gennaro (Ed.), *Remington: the Science and Practice of Pharmacy*, 19th ed., pp. 1650-1651 (1995).
- Qureshi, et al., "Pharmacokinetics of Two Enteric-Coated Ketoprofen Products in Humans with or Coadministration of Omeprazole and Comparison with Dissolution Findings," *Pharmaceutical Research*, 11(11), pp. 1669-1672 (1994).
- Raskin, et al., "Misoprostol Dosage in the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastric and Duodenal Ulcers: A Comparison of Three Regimens," *Ann. Intern. Med.*, 123(5), pp. 344-350 (Sep. 1995).
- Richardson et al., "Proton pump inhibitors, pharmacology and rationale for use in gastrointestinal disorders," *Drugs*, 56(3), pp. 307-335 (1998).
- Robinson, et al., "Effects of Ranitidine Gastroduodenal Mucosal Damage Induced by Nonsteroidal Anti-inflammatory Drugs," *Dig. Dis. Sci.*, 34(3), pp. 424-428 (Mar. 1989).
- Roth, et al., "Cimetidine Therapy in Nonsteroidal Anti-inflammatory Drug Gastropathy: Double-blind Long-term Evaluation," *Arch. Intern. Med.*, 147, pp. 1798-1801 (1987).
- Rubinstein, "Gastrointestinal anatomy physiology and permeation pathways," *Enhancement in Drug Discovery*, CRC Press, pp. 3-35 (2007).
- Sangiah et al., "Effects of misoprostol and omeprazole on basal gastric pH and free acid content in horses," *Res. Vet. Sci.*, 47(3), pp. 350-354 (1989).
- Savarino et al., "Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients," *Digestive Diseases and Sciences*, 43, pp. 459-463 (1998).
- Scarpignato et al., *Gastroenterology International*; pp. 186-215 (1999).
- Scheinman et al., "NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management," *Dig. Dis.*, 12, pp. 210-222 (1994).
- Scheinman et al., "Omeprazole ameliorates aspirin-induced gastroduodenal injury," *Digestive Diseases and Sciences*, 39(1), pp. 97-103 (1994).
- Scheinman, *Seminars in Arthritis and Rheumatism*, pp. 201-210 (1992).
- Scott and Sundell, "Inhibition of H+K+ ATPase by SCH 28080 and SCH 32651," *European Journal of Pharmacology*, 112, pp. 268-270 (1985).
- Seitz et al., "Tablet coating," in *The theory and practice of industrial pharmacy*, Lachman et al. eds., Lea and Febiger, pp. 346-373 (1986).
- Selway et al., "Potential hazards of long-term acid suppression," *Scand. J. Gastroenterol.*, 25, Supp. 178, pp. 85-92 (1990).
- Sharma et al., "Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole," *Am. J. Health-Syst. Pharm.*, 56, Supp. 4, pp. S18-S21 (1999).
- Silverman, *The Organic Chemistry of Drug Design and Drug Action*, 2nd Edition, Academic Press, pp. 102 & 527 (2004).
- Silverstein et al., "Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis; the CLASS study: A randomized controlled trial," *JAMA*, 284, pp. 1247-1255 (2000).
- Silverstein, et al., "Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs," *Ann. Intern. Med.*, 123(4), pp. 241-249 (1995).
- Simon English translation—Simon, et al., "Schutzwirkung von Omeprazol gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 45, pp. 701-703 (1995).
- Simon, et al., "Schutzwirkung von Omeprazol gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 45, pp. 701-703 (1995).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.